Quest Diagnostics Incorporated (NYSE:DGX - Free Report) - Equities research analysts at Zacks Research increased their FY2025 earnings estimates for Quest Diagnostics in a report released on Thursday, May 16th. Zacks Research analyst M. Mondal now expects that the medical research company will post earnings per share of $9.28 for the year, up from their previous forecast of $9.27. The consensus estimate for Quest Diagnostics' current full-year earnings is $8.78 per share. Zacks Research also issued estimates for Quest Diagnostics' Q4 2025 earnings at $2.34 EPS.
Quest Diagnostics (NYSE:DGX - Get Free Report) last announced its earnings results on Tuesday, April 23rd. The medical research company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.86 by $0.18. The company had revenue of $2.37 billion during the quarter, compared to the consensus estimate of $2.29 billion. Quest Diagnostics had a net margin of 9.11% and a return on equity of 15.52%. Quest Diagnostics's revenue was up 1.7% compared to the same quarter last year. During the same period last year, the firm earned $2.04 earnings per share.
DGX has been the subject of several other reports. StockNews.com downgraded shares of Quest Diagnostics from a "buy" rating to a "hold" rating in a research note on Friday, May 3rd. Jefferies Financial Group upgraded shares of Quest Diagnostics from a "hold" rating to a "buy" rating and raised their target price for the company from $140.00 to $155.00 in a research note on Wednesday, February 7th. Citigroup lifted their price objective on shares of Quest Diagnostics from $135.00 to $145.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 24th. Mizuho lifted their price objective on shares of Quest Diagnostics from $150.00 to $155.00 and gave the stock a "buy" rating in a research note on Wednesday, April 24th. Finally, Leerink Partnrs reiterated a "market perform" rating on shares of Quest Diagnostics in a research note on Monday, February 26th. Ten research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $146.17.
View Our Latest Stock Analysis on Quest Diagnostics
Quest Diagnostics Stock Up 1.3 %
DGX traded up $1.91 during trading on Friday, hitting $144.34. The stock had a trading volume of 1,422,743 shares, compared to its average volume of 1,039,167. The company has a market capitalization of $16.03 billion, a PE ratio of 19.24, a PEG ratio of 3.06 and a beta of 0.88. Quest Diagnostics has a twelve month low of $119.59 and a twelve month high of $145.58. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.89 and a current ratio of 0.97. The stock has a 50 day simple moving average of $132.66 and a two-hundred day simple moving average of $132.58.
Quest Diagnostics Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Monday, July 22nd. Shareholders of record on Monday, July 8th will be issued a $0.75 dividend. This represents a $3.00 annualized dividend and a yield of 2.08%. The ex-dividend date of this dividend is Monday, July 8th. Quest Diagnostics's payout ratio is 38.22%.
Insider Buying and Selling at Quest Diagnostics
In other Quest Diagnostics news, Director Vicky B. Gregg sold 2,500 shares of the company's stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $126.64, for a total value of $316,600.00. Following the completion of the transaction, the director now owns 16,329 shares in the company, valued at $2,067,904.56. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Quest Diagnostics news, SVP Michael E. Prevoznik sold 5,611 shares of the company's stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $125.88, for a total value of $706,312.68. Following the completion of the transaction, the senior vice president now owns 38,478 shares in the company, valued at $4,843,610.64. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Vicky B. Gregg sold 2,500 shares of the company's stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $126.64, for a total transaction of $316,600.00. Following the completion of the transaction, the director now owns 16,329 shares of the company's stock, valued at approximately $2,067,904.56. The disclosure for this sale can be found here. Over the last three months, insiders have sold 16,910 shares of company stock valued at $2,159,602. 0.79% of the stock is owned by insiders.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the stock. Altshuler Shaham Ltd acquired a new position in shares of Quest Diagnostics during the 4th quarter worth about $26,000. NBC Securities Inc. purchased a new stake in shares of Quest Diagnostics in the 3rd quarter valued at approximately $25,000. BKM Wealth Management LLC purchased a new stake in shares of Quest Diagnostics in the 4th quarter valued at approximately $29,000. VisionPoint Advisory Group LLC boosted its position in shares of Quest Diagnostics by 100.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 218 shares of the medical research company's stock worth $27,000 after purchasing an additional 109 shares during the period. Finally, Spartan Planning & Wealth Management purchased a new position in shares of Quest Diagnostics during the 4th quarter worth approximately $31,000. Institutional investors and hedge funds own 88.06% of the company's stock.
Quest Diagnostics Company Profile
(Get Free Report)
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
Further Reading
- Five stocks we like better than Quest Diagnostics
- How to Most Effectively Use the MarketBeat Earnings Screener
- Take-Two Interactive Software Offers 2nd Chance for Investors
- Golden Cross Stocks: Pattern, Examples and Charts
- How to Capture the Benefits of Dividend Increases
- Analysts Still Want Double-Digit Upside Out of Applied Materials
→ Elon to Transform U.S. Economy? (From Porter & Company) (Ad)
Should you invest $1,000 in Quest Diagnostics right now?
Before you consider Quest Diagnostics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quest Diagnostics wasn't on the list.
While Quest Diagnostics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
10 Best Cheap Stocks to Buy Now
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
